These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18721327)

  • 1. Breakpoints for posaconazole susceptibility testing: background and discussion about the need of establishing values.
    Fleck R; Hof H
    Mycoses; 2008 Sep; 51 Suppl 2():1-4. PubMed ID: 18721327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posaconazole: a broad-spectrum triazole antifungal.
    Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
    Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole: clinical pharmacology and potential for management of fungal infections.
    Groll AH; Walsh TJ
    Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
    Nagappan V; Deresinski S
    Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.
    Hof H
    Mycoses; 2006; 49 Suppl 1():2-6. PubMed ID: 16961575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal activity of posaconazole against Candida spp. and non-Candida clinical yeasts isolates.
    Carrillo-Muñoz AJ; Tur-Tur C; Hernández-Molina JM; Quindós G; Marcos-Arias C; Eraso E; Cárdenes D; Ortiz-Maestro O; Santos P; Estivill D; Guardia C; Giusiano G
    Rev Esp Quimioter; 2010 Sep; 23(3):122-5. PubMed ID: 20844842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
    Groll AH; Walsh TJ
    Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The latest data on posaconazole].
    Paugam A
    Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole: a new broad-spectrum antifungal agent.
    Kwon DS; Mylonakis E
    Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole: a next-generation triazole antifungal.
    Farowski F; Vehreschild JJ; Cornely OA
    Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
    Smith WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):165-81. PubMed ID: 19254165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antifungal susceptibility testing in patient management.
    Forrest G
    Curr Opin Infect Dis; 2006 Dec; 19(6):538-43. PubMed ID: 17075328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EUCAST technical note on posaconazole.
    Arendrup MC; Cuenca-Estrella M; Donnelly JP; Hope W; Lass-Flörl C; Rodriguez-Tudela JL;
    Clin Microbiol Infect; 2011 Nov; 17(11):E16-7. PubMed ID: 21923779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi.
    Messer SA; Diekema DJ; Hollis RJ; Boyken LB; Tendolkar S; Kroeger J; Pfaller MA
    J Clin Microbiol; 2007 Apr; 45(4):1322-4. PubMed ID: 17267623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test.
    Kondori N; Svensson E; Mattsby-Baltzer I
    Mycoses; 2011 Sep; 54(5):e318-22. PubMed ID: 20557462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.